Journal
JOURNAL OF CANCER METASTASIS AND TREATMENT
Volume 8, Issue -, Pages -Publisher
OAE PUBLISHING INC
DOI: 10.20517/2394-4722.2021.174
Keywords
Matrix metalloproteinase; membrane-type; osteosarcoma; MT1-MMP
Categories
Funding
- Bone Cancer Research Trust [BCRT 6218]
Ask authors/readers for more resources
This review summarizes the expression and potential role of Membrane - type 1 matrix metalloproteinase (MT1-MMP) in osteosarcoma (OS), and assesses its therapeutic potential as a drug target. The findings suggest that exploiting the expression and proteolytic capacity of MT1-MMP could lead to the discovery of novel, safer and more selective drugs for the treatment of OS.
The dysregulation of Membrane - type 1 matrix metalloproteinase (MT1- MMP) has been extensively studied in numerous cancer types, and plays key roles in angiogenesis, cancer progression, and metastasis. MT1-MMP is a predictor of poor prognosis in osteosarcoma (OS), yet the molecular mechanisms of disease progression are unclear. This review provides a summary of the literature relating to the gene and protein expression of MT1-MMP (MMP-14) in OS clinical samples, evaluates the expression in cell lines and experimental models, and analyses its potential role in the progression and metastasis of OS. In addition, the therapeutic potential of MT1-MMP as a drug target has been assessed. Due to the biological complexity of MMPs, inhibition has proven to be challenging. However, exploiting the expression and proteolytic capacity of MT1-MMP could open new avenues in the search for novel, safer and selective drugs for use in OS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available